The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 11.5% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 20%. Insiders have been net sellers over the past quarter. Since the last review it entered the Tech 100.
Price as of 4 Nov 2026Daily close, not a live quote
Screened 2026-11-04 · the tape above runs as of 12:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price6.25 USD at the 4 Nov 2026 close
- Fair value7.97. Our model only; no analyst estimate to cross-check.
- Our value readUndervalued vs our fair value, as of 4 Nov 2026
- Our regime readDistribution, as of 4 Nov 2026
- Ethical screenPasses
- Last reviewed4 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $7.97 to $12.50, base estimate $7.97 (screen dated 2026-11-04).
- Trend Distribution
- Insiders insiders sold, $36,295, latest filing 2026-09-17
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Eltek Ltd. holds its Distribution at $6.25. The statistical read favours the sellers, held for 15 days.
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the sellers, held for 15 days |
| Price at the screen | $6.25 |
| Valuation | N/A trailing · 6.11 forward price to earnings |
| Values screen | PASS |
| Beta | 0.69 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 11.77% | Below 33% | Interest-bearing debt is just 11.8% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 22.32% | Below 33% | Cash held in interest-bearing accounts and securities is 22.3% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
| Revenue purity | 1.11% | Below 5% | Only 1.1% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Clears, in Plain English
Eltek clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 12%, inside the ~33% line, and interest is about 1% of its income, under the ~5% line, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ELTK's ethical verdict changes
Today ELTK passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our model only; no analyst estimate to cross-check.
Our analysis reads Undervalued vs our fair value, as of 4 Nov 2026: it trades at roughly a 22% discount to our $7.97 fair value, weak competitive moat.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 21.6% discount to the base estimate.
Where our models see it going: fair-value estimate $7.97, with a range of $7.97 to $12.50, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it stands out
Trading at 6.1x forward earnings, with a weak competitive moat and minimal debt. That is a 22% discount to our $7.97 fair value: the market is pricing it cautiously while the fundamentals argue otherwise.
| Forward P/E | 6.1xvery cheap relative to earnings |
| EPS, trailing | -0.91 |
| EPS, forward | 1.08 |
| Revenue growth | -7.9%revenue is shrinking |
| Profit margin | -12.7%currently unprofitable |
| Return on equity | -13.8%not currently earning a positive return on equity |
| FCF yield | 5.33% |
| Dividend yield | 230.00% |
| Debt to equity | 0.29minimal debt: a conservative balance sheet |
| Current ratio | 2.15comfortably covers its short-term bills |
| Beta | 0.69steadier than the market |
| Short interest, float | 0.00% |
| 52-week range | 6.38 - 11.59 |
| Moat | WEAK |
| Market cap | $44M |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeELTK trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 16.4% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 20%. Insiders have been net sellers over the past quarter.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 20%. Insiders have been net sellers over the past quarter.
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 2.5% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 20%. Insiders have been net sellers over the past quarter.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 7.3% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 20%.
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.1% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 20%.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 9%. Our forward projection puts the odds of a 10% gain over the next month near 20%.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows negative risk-adjusted returns.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Eltek Receives $6.8 Million Of Purchase Orders From An International Customer Yahoo Finance · 6 Oct 2026
- Eltek Ltd. Announces CEO Transition: Retirement of Eli Yaffe and Appointment of Ron Freund as the Company's CEO Yahoo Finance · 9 Sep 2026
- Eltek (ELTK) Q2 2026 Earnings Call Transcript Motley Fool · 25 Aug 2026
- Eltek (ELTK) Q2 2026 Earnings Call Transcript Yahoo Finance · 25 Aug 2026
- Eltek Ltd (ELTK) (Q2 2026) Earnings Call Highlights: Navigating Operational Challenges Amid ... GuruFocus.com · 23 Aug 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-17 | Dovev Gad | Reporting Person: Former Dir. | S - Sale+OE | 4,260 | $36,295 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $7.96 | +13.1% | · | $1,131 | +13.1% |
| 2 months | $8.05 | +11.8% | · | $1,118 | +11.8% |
| 3 months | $9.14 | -1.5% | · | $985 | -1.5% |
| 6 months | $9.34 | -3.6% | · | $964 | -3.6% |
| 1 year | $9.84 | -8.5% | · | $915 | -8.5% |
| 2 years | $10.71 | -16.0% | $0.19 | $858 | -14.2% |
| 3 years | $9.15 | -1.6% | $0.41 | $1,029 | +2.9% |
| 5 years | $5.65 | +59.2% | $0.58 | $1,694 | +69.4% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever ELTK does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.